In some instances, (such as TFF1 ), combining chromatin modifying agents with fulvestrant resulted in stronger downregulation than either single agent, although this coincided with an unexplained trend towards increased ER occupancy at ER target gene promoters and enhancers compared to each single agent.
← all excerpts
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
1
—
—